Experimental Drug Shows Promise for Disfiguring Tumor Condition

THURSDAY, Dec. 29, 2016 — An experimental drug has shown promise in treating benign, but disfiguring, tumors caused by a genetic disorder.
The oral medication, selumentinib, caused tumors to shrink in 17 of 24 children afflicted with…
Source: Topamax